Most of what is written about alpha-GPC concerns memory and attention. A separate and smaller body of research measured something else entirely — force, power and growth hormone in athletes — and the two literatures get quoted as though they were one. They are not, and the differences are the interesting part.
Two literatures, one molecule
The cognition studies give alpha-GPC daily for weeks or months and measure test scores. The exercise studies mostly give a single dose thirty to ninety minutes before a task and measure force; the exception is Bellar et al. 2015, which dosed 600 mg a day for six days.
Different designs, different endpoints, and largely different people. A result from one does not carry across to the other, and the marketing habit of stacking them into a single list of benefits is the error this page is about.
Whether the compound reaches the brain at all is a separate question again, handled in what acetylcholine does.
The first thread: growth hormone
Alpha-GPC administration increased the growth hormone response to growth-hormone-releasing hormone in both young and elderly volunteers (Ceda et al., Hormone and Metabolic Research, 1992). The groups were small, which is stated here because it is the study's main limitation.
A later trial gave 1,000 mg to young men before resistance exercise and reported higher peak growth hormone and increased fat oxidation against placebo (Kawamura et al., Nutrition, 2012; n=8, single dose, crossover).
The hormone response is a genuine, repeatedly observed finding. But post-exercise growth hormone spikes are brief, and a transient hormonal change has not been shown here to produce any change in muscle size or performance. The endpoint is a signal, not an outcome.
The second thread: force production
The most-cited result is a conference abstract
The frequently quoted finding that 600 mg increased peak force during resistance exercise was published as a conference abstract with seven participants (Ziegenfuss, Landis and Hofheins, Journal of the International Society of Sports Nutrition, 2008; n=7).
An abstract has not been through full peer review and reports a fraction of the methods. It is a reason to run the study, not a result to build a claim on.
The full paper found one thing and not another
College-aged men took 600 mg a day for six days in a crossover against caffeine and placebo. Upper-body isometric force was higher after alpha-GPC than after placebo; the lower-body measure did not separate (Bellar, LeBlanc and Campbell, Journal of the International Society of Sports Nutrition, 2015; n=13).
A split result in thirteen people is the honest headline. Reporting only the half that moved is how this literature acquired its reputation.
The largest of them is still under fifty people
A single dose of 250 mg or 500 mg was tested against placebo across a battery of physical and psychomotor tasks in healthy young adults, with some measures separating and others not (Marcus et al., Journal of the International Society of Sports Nutrition, 2017; n=48).
The exercise studies, side by side
| Study | Who | Dose | Measured | Result |
|---|---|---|---|---|
| Ceda et al., 1992 | Young and elderly volunteers, small groups | Single administration | Growth hormone response | Response increased |
| Ziegenfuss et al., 2008 (abstract) | n=7 | 600 mg, acute | Peak force, growth hormone | Both reported higher; abstract only |
| Kawamura et al., 2012 | n=8, young men | 1,000 mg, acute | Growth hormone, fat oxidation | Both higher than placebo |
| Bellar et al., 2015 | n=13, college-aged men | 600 mg/day, six days | Isometric force, upper and lower body | Upper body only |
| Marcus et al., 2017 | n=48, healthy young adults | 250 or 500 mg, acute | Physical and psychomotor battery | Mixed across measures |
What is weak about all of it
The samples
Every entry in that table has fewer than fifty participants. One is a conference abstract. With one exception, the populations are young and mostly male, which is the least representative group available for a product sold to adults over forty.
The durations
Days, not months. Nothing above tells anyone what six months of use does, because nobody has run that study.
The mechanism people reach for
Acetylcholine is the transmitter at the junction between motor nerve and muscle fibre, so a choline-donating compound has an obvious story available to it — set out in full in what acetylcholine actually does.
The story is plausible and it is not evidence. Plausibility explains why the trials were worth running; it does not stand in for their results.
The 1986 finding that started it
Plasma choline concentrations were measured in runners before and after the Boston Marathon and had fallen substantially by the finish (Conlay et al., New England Journal of Medicine, 1986; published as a research letter).
That observation launched a decade of interest in choline as an endurance aid. It is a real measurement in real athletes, and it says nothing on its own about whether replacing the choline helps.
And the trial that followed it, which failed
Choline supplementation was tested in soldiers performing loaded marching and physical tasks. Plasma choline rose as intended. Performance did not improve against placebo (Warber et al., International Journal of Sport Nutrition and Exercise Metabolism, 2000).
This is the null result that belongs in every article on the subject and appears in almost none of them. Correcting a measured fall in a substrate did not produce the outcome the fall was supposed to explain.
The doses, each stated with its population
In the exercise work
Roughly 250 to 1,000 mg, usually as one dose before a task, in young healthy adults.
What the trials used
Attention and memory trials in healthy adults have run at single doses of roughly 250 to 630 mg. Larger figures do circulate, and they come from trials conducted in people with diagnosed cognitive impairment — a different population, treated for a diagnosis, and not a benchmark for anyone else. The full accounting is in how much alpha-GPC the research actually used.
Two ranges from two literatures, overlapping by accident rather than because anyone established a common dose.
The cardiovascular question, which is the serious one
What the cohort reported
In South Korea alpha-GPC is a prescription medicine, which means a national claims database can follow everyone who took it. A cohort study using that database reported a higher incidence of stroke over ten years among people prescribed alpha-GPC than among matched comparators (Lee et al., JAMA Network Open, 2021).
Why the effect size is not quoted here
The design does not allow the effect size to be read as a treatment effect: the people prescribed it were prescribed it for cognitive complaints, and cognitive complaints in older adults travel with vascular disease. Confounding by indication is the obvious explanation and the study cannot exclude it.
What it does establish is that the question is open. That is a different thing from a clean bill of health, and anyone quoting alpha-GPC's benefits without mentioning this is quoting half a literature.
The pathway behind the concern
Gut bacteria convert dietary choline to trimethylamine, which the liver oxidises to trimethylamine N-oxide. Higher circulating TMAO has been associated with cardiovascular events (Tang et al., New England Journal of Medicine, 2013; n=4,007, three years' follow-up, patients undergoing elective coronary angiography).
That is an association in a high-risk clinical population, not a demonstration that a supplement causes harm. It is a reason for care and for stating the open question rather than for alarm.
What this changes about how a label should read
It removes any basis for a dose-superiority claim. A category with small trials, mixed results and an unresolved safety question is not one where the correct move is to print a bigger number than the competition.
What survives is narrower and checkable: which compound is in the capsule, how much of it, and whether the form is stated at all. That is the comparison made in alpha-GPC versus choline bitartrate.
Where we stand
Weal Focus contains 300 mg of alpha-GPC, printed with the form named, and is sold as a focus formula rather than a training product. Nothing on this page is offered as evidence that it improves athletic performance.
The exercise literature is included because it exists and because leaving it out would be the same selective quoting the article objects to. How quickly any of it would be expected to register is a separate question, in how long a supplement actually takes.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Sources for the claims and figures on this page, with the population studied in each, are on our citations page.